Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
DOI: https://doi.org/10.2147/JHC.S344559
2022-06-01
Journal of Hepatocellular Carcinoma
Abstract:Muhammad Imran Ahmad, 1 Muhammad Umair Khan, 2, 3 Sudha Kodali, 1, 4 Akshay Shetty, 1, 4 S Michelle Bell, 4 David Victor 1, 4 1 Lynda K and David M Underwood Center for Digestive Disorders, Division of Gastroenterology and Hepatology, Houston Methodist Hospital Houston, Houston, TX, USA; 2 Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar; 3 ECPE- Executive and Continuing Professional Education, Harvard T.H Chan School of Public Health, Boston, MA, 02115-5810, USA; 4 Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, USA Correspondence: David Victor, Associate Professor of Clinical Medicine, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, USA, Email Obesity has been labeled as the global pandemic of the 21st century, resulting from a sedentary lifestyle and caloric excess. Nonalcoholic fatty liver disease (NAFLD), characterized by excessive hepatic steatosis, is strongly associated with obesity and metabolic syndrome and is estimated to be present in one-quarter of the world population, making it the most common cause of the chronic liver disease (CLD). NAFLD spectrum varies from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. The burden of NAFLD has been predicted to increase in the coming decades resulting in increased rates of decompensated cirrhosis, hepatocellular carcinoma (HCC), and liver-related deaths. In the current review, we describe the pathophysiology of NAFLD and NASH, risk factors associated with disease progression, related complications, and mortality. Later, we have discussed the changing epidemiology of HCC, with NAFLD emerging as the most common cause of CLD and HCC. We have also addressed the risk factors of HCC development in the NAFLD population (including demographic, metabolic, genetic, dietary, and lifestyle factors), presentation of NAFLD-associated HCC, its prognosis, and the issue of HCC development in non-cirrhotic NAFLD. Lastly, the problems related to HCC screening in the NAFLD population, the remaining challenges, and future directions, especially the need to identify the high-risk individuals, will be discussed. We will conclude the review by summarizing the clinical evidence for treating fibrosis and preventing HCC in those at risk with NAFLD-associated HCC. Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatocellular carcinoma, metabolic syndrome, HCC screening The World Health Organization estimates that 39% of adults are overweight, while 13% are obese. 1 The burden of obesity and associated comorbidities is expected to rise in the coming decades, especially since 40 million children were estimated to be overweight or obese in 2018. 1,2 Obesity is a known risk factor for cardiovascular diseases. 3,4 It is closely associated with metabolic complications, including diabetes mellitus (DM), hyperlipidemia (HLD), and nonalcoholic fatty liver disease (NAFLD). 5 High body mass index (BMI) is associated with an increased risk of different types of cancers, including liver and colon cancer. 6,7 More frightening is the fact that obesity doubles the mortality risk in patients with liver cancer. 8 NAFLD is the most common cause of chronic liver disease (CLD). It is characterized by hepatic steatosis (HS) either by imaging or histology without secondary causes of hepatic fat accumulation, such as excessive alcohol consumption (daily ≥30 g for men and ≥20 g for women), medications, or other chronic liver diseases. 9,10 NAFLD includes two pathologically distinct conditions: nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL is defined as the presence of ≥5% HS without evidence of hepatocellular injury in the form of hepatocyte ballooning. NASH is characterized by steatosis with inflammation and hepatocyte ballooning with or without liver fibrosis. 11 Recently, it has been recommended to rename NAFLD as Metabolic dysfunction-associated fatty liver disease (MAFLD). This new definition has been proposed to better encapsulate the spectrum of fatty liver disease. MAFLD diagnosis is based on hepatic steatosis (based on histological, imaging, or blood biomarker) and one of the following three conditions: type 2 diabetes mellitus, overweight/obesity, or metabolic dysregulation. 12 However, this manuscript will be limited to the prior definition of NAFLD rather the entire umbrella of MAFLD disease. NAFLD is often labeled as the liver manifestation of metabolic syndrome and is strongly associated with obesity, type 2 diabetes mel -Abstract Truncated-
oncology